MXPA04001645A - Dispositivo de control de insectos que contiene coumaphos y diazinon para el tratamiento prolongado de animales. - Google Patents
Dispositivo de control de insectos que contiene coumaphos y diazinon para el tratamiento prolongado de animales.Info
- Publication number
- MXPA04001645A MXPA04001645A MXPA04001645A MXPA04001645A MXPA04001645A MX PA04001645 A MXPA04001645 A MX PA04001645A MX PA04001645 A MXPA04001645 A MX PA04001645A MX PA04001645 A MXPA04001645 A MX PA04001645A MX PA04001645 A MXPA04001645 A MX PA04001645A
- Authority
- MX
- Mexico
- Prior art keywords
- parkinson
- brain
- treatment
- compositions
- product
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/397—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having four-membered rings, e.g. azetidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurosurgery (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Los insectos molestos son controlados fijando un dispositivo para el control de insectos en el cuerpo del animal a tratar. El dispositivo controlador de insectos es un articulo moldeado, preferentemente en forma de un herrete para las orejas, que ha sido formado a partir de una mezcla en polvo de coumaphos y diazinon, cloruro de polivinilo y un plastificante. Los ingredientes activos coumaphos y diazinon se emplean generalmente en una cantidad que prolongara la actividad insecticida sin ir en detrimento de las caracteristicas adecuadas del dispositivo.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
FR0111200A FR2829028B1 (fr) | 2001-08-29 | 2001-08-29 | Association d'un antagoniste du recepteur cb1 et d'un produit qui active la neurotransmission dopaminergique dans le cerveau, les compositions pharmaceutiques les contenant et leur utilisation pour le traitement de la maladie de |
PCT/FR2002/002946 WO2003020314A1 (fr) | 2001-08-29 | 2002-08-28 | Compositions pour le traitement de la maladie de parkinson contenant un antagoniste du recepteur cb1 et un produit qui active la neurotransmission dopaminergique dans le cerveau |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA04001645A true MXPA04001645A (es) | 2004-05-31 |
Family
ID=8866792
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA04001645A MXPA04001645A (es) | 2001-08-29 | 2002-08-28 | Dispositivo de control de insectos que contiene coumaphos y diazinon para el tratamiento prolongado de animales. |
Country Status (16)
Country | Link |
---|---|
US (2) | US7217705B2 (es) |
EP (2) | EP1649849A3 (es) |
JP (2) | JP2005505551A (es) |
AR (1) | AR036302A1 (es) |
AT (1) | ATE328609T1 (es) |
AU (2) | AU2002337277B2 (es) |
CA (1) | CA2458348A1 (es) |
CY (1) | CY1105341T1 (es) |
DE (1) | DE60212148T2 (es) |
DK (1) | DK1423145T3 (es) |
ES (1) | ES2263816T3 (es) |
FR (1) | FR2829028B1 (es) |
IL (2) | IL160557A0 (es) |
MX (1) | MXPA04001645A (es) |
PT (1) | PT1423145E (es) |
WO (1) | WO2003020314A1 (es) |
Families Citing this family (52)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE19814084B4 (de) * | 1998-03-30 | 2005-12-22 | Lts Lohmann Therapie-Systeme Ag | D2-Agonist enthaltendes transdermales therapeutisches System zur Behandlung des Parkinson-Syndroms und Verfahren zu seiner Herstellung |
DE10041479A1 (de) * | 2000-08-24 | 2002-03-14 | Sanol Arznei Schwarz Gmbh | Neue pharmazeutische Zusammensetzung zur Verabreichung von N-0923 |
DE10066158B4 (de) * | 2000-08-24 | 2007-08-09 | Neurobiotec Gmbh | Verwendung eines transdermalen therapeutischen Systems zur Behandlung des Restless-Legs-Syndroms |
US20030027793A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal treatment of parkinson's disease |
US20030026830A1 (en) * | 2001-05-08 | 2003-02-06 | Thomas Lauterback | Transdermal therapeutic system for parkinson's disease inducing high plasma levels of rotigotine |
US20030139386A1 (en) * | 2001-12-21 | 2003-07-24 | Sophie Cote | Pharmaceutical compositions based on azetidine derivatives |
US20060263419A1 (en) * | 2002-03-12 | 2006-11-23 | Hans-Michael Wolff | Transdermal therapeutic system for Parkinson's Disease |
US20040048779A1 (en) * | 2002-05-06 | 2004-03-11 | Erwin Schollmayer | Use of rotigotine for treating the restless leg syndrome |
DE10234673B4 (de) * | 2002-07-30 | 2007-08-16 | Schwarz Pharma Ag | Heißschmelz-TTS zur Verabreichung von Rotigotin und Verfahren zu seiner Herstellung sowie Verwendung von Rotigotin bei der Herstellung eines TTS im Heißschmelzverfahren |
US8246980B2 (en) * | 2002-07-30 | 2012-08-21 | Ucb Pharma Gmbh | Transdermal delivery system |
US8211462B2 (en) * | 2002-07-30 | 2012-07-03 | Ucb Pharma Gmbh | Hot-melt TTS for administering rotigotine |
US7129239B2 (en) | 2002-10-28 | 2006-10-31 | Pfizer Inc. | Purine compounds and uses thereof |
US7247628B2 (en) | 2002-12-12 | 2007-07-24 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
DE10261696A1 (de) | 2002-12-30 | 2004-07-15 | Schwarz Pharma Ag | Vorrichtung zur transdermalen Verabreichung von Rotigotin-Base |
US7329658B2 (en) | 2003-02-06 | 2008-02-12 | Pfizer Inc | Cannabinoid receptor ligands and uses thereof |
US7176210B2 (en) | 2003-02-10 | 2007-02-13 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7268133B2 (en) | 2003-04-23 | 2007-09-11 | Pfizer, Inc. Patent Department | Cannabinoid receptor ligands and uses thereof |
US7145012B2 (en) | 2003-04-23 | 2006-12-05 | Pfizer Inc. | Cannabinoid receptor ligands and uses thereof |
US7141669B2 (en) | 2003-04-23 | 2006-11-28 | Pfizer Inc. | Cannabiniod receptor ligands and uses thereof |
US7232823B2 (en) | 2003-06-09 | 2007-06-19 | Pfizer, Inc. | Cannabinoid receptor ligands and uses thereof |
CN1802351A (zh) | 2003-06-11 | 2006-07-12 | 麦克公司 | 被取代的3-烷基和3-链烯基氮杂环丁烷衍生物 |
DE10334187A1 (de) * | 2003-07-26 | 2005-03-03 | Schwarz Pharma Ag | Substituierte 2-Aminotetraline zur Behandlung von Depressionen |
DE10334188B4 (de) * | 2003-07-26 | 2007-07-05 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung von Depressionen |
DE10359528A1 (de) * | 2003-12-18 | 2005-07-28 | Schwarz Pharma Ag | (S)-2-N-Propylamino-5-hydroxytetralin als D3-agonistisches Therapeutikum |
EP1547592A1 (en) * | 2003-12-23 | 2005-06-29 | Schwarz Pharma Ag | Intranasal formulation of rotigotine |
DE10361258A1 (de) * | 2003-12-24 | 2005-07-28 | Schwarz Pharma Ag | Verwendung von substituierten 2-Aminotetralinen zur vorbeugenden Behandlung von Morbus Parkinson |
CA2556565A1 (en) * | 2004-02-17 | 2005-08-25 | Laboratorios Del Dr. Esteve S.A. | Substituted azetidine compounds, their preparation and use as medicaments |
ES2244314B1 (es) * | 2004-02-17 | 2007-02-01 | Laboratorios Del Dr. Esteve, S.A. | Compuestos azetidinicos sustituidos, su preparacion y su aplicacion como medicamentos. |
US20050197385A1 (en) * | 2004-02-20 | 2005-09-08 | Schwarz Pharma Ag | Use of rotigotine for treatment or prevention of dopaminergic neuron loss |
DE102004014841B4 (de) * | 2004-03-24 | 2006-07-06 | Schwarz Pharma Ag | Verwendung von Rotigotin zur Behandlung und Prävention des Parkinson-Plus-Syndroms |
TW200602314A (en) | 2004-05-28 | 2006-01-16 | Tanabe Seiyaku Co | A novel pyrrolidine compound and a process for preparing the same |
CA2613235A1 (en) | 2005-06-30 | 2007-01-11 | Prosidion Limited | Gpcr agonists |
US20070060638A1 (en) * | 2005-08-26 | 2007-03-15 | Olmstead Mary C | Methods and therapies for potentiating therapeutic activities of a cannabinoid receptor agonist via administration of a cannabinoid receptor antagonist |
US7906652B2 (en) | 2005-11-28 | 2011-03-15 | Merck Sharp & Dohme Corp. | Heterocycle-substituted 3-alkyl azetidine derivatives |
TWI392670B (zh) * | 2006-06-22 | 2013-04-11 | Ucb Pharma Gmbh | 經取代的2-胺基萘滿之於製造用於預防、減緩及/或治療各種類型疼痛之藥物上的用途 |
BRPI0806312A2 (pt) | 2007-01-04 | 2011-09-06 | Prosidion Ltd | agonistas cgpr piperidina |
GB0700122D0 (en) | 2007-01-04 | 2007-02-14 | Prosidion Ltd | GPCR agonists |
PE20081849A1 (es) | 2007-01-04 | 2009-01-26 | Prosidion Ltd | Derivados de piperidin-4-il-propoxi-benzamida como agonistas de gpcr |
AR064735A1 (es) | 2007-01-04 | 2009-04-22 | Prosidion Ltd | Agonistas de gpcr y composicion farmaceutica en base al compuesto |
EP2377863A1 (en) | 2007-01-04 | 2011-10-19 | Prosidion Limited | Piperidine GPCR agonists |
EP1987815A1 (en) * | 2007-05-04 | 2008-11-05 | Schwarz Pharma Ag | Oronasopharyngeally deliverable pharmaceutical compositions of dopamine agonists for the prevention and/or treatment of restless limb disorders |
GB0720390D0 (en) | 2007-10-18 | 2007-11-28 | Prosidion Ltd | G-Protein coupled receptor agonists |
GB0720389D0 (en) | 2007-10-18 | 2008-11-12 | Prosidion Ltd | G-Protein Coupled Receptor Agonists |
CN101970422B (zh) * | 2007-11-28 | 2014-10-22 | Ucb制药有限公司 | 罗替高汀的多晶型物 |
US20090247537A1 (en) * | 2008-03-25 | 2009-10-01 | William Dale Overfield | Methods for preventing or treating bruxism using dopaminergic agents |
AU2010238732B2 (en) | 2009-04-22 | 2015-06-11 | Janssen Pharmaceutica Nv | Azetidinyl diamides as monoacylglycerol lipase inhibitors |
EP2281559A1 (en) | 2009-06-26 | 2011-02-09 | UCB Pharma GmbH | Pharmaceutical composition comprising rotigotine salts (acid or Na), especially for iontophoresis |
HUE039447T2 (hu) | 2009-12-22 | 2018-12-28 | Ucb Biopharma Sprl | Polivinilpirrolidon rotigotin nem kristályos formája szilárd diszperziójának stabilizálására |
US8575363B2 (en) * | 2010-10-22 | 2013-11-05 | Janssen Pharmaceutica N.V. | Amino-pyrrolidine-azetidine diamides as monoacylglycerol lipase inhibitors |
US8513423B2 (en) | 2010-10-22 | 2013-08-20 | Janssen Pharmaceutica, Nv | Piperidin-4-yl-azetidine diamides as monoacylglycerol lipase inhibitors |
US9248111B2 (en) * | 2011-03-01 | 2016-02-02 | Pharnext | Therapeutic approaches for treating parkinson's disease |
WO2022245900A2 (en) * | 2021-05-21 | 2022-11-24 | Murphy Brian Stuart | Compositions for treating inflammatory, neurologic and/or vascular conditions and methods of use thereof |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
US5635159A (en) * | 1994-08-26 | 1997-06-03 | Abbott Laboratories | Aerosol drug formulations containing polyglycolyzed glycerides |
US5562917A (en) * | 1994-12-23 | 1996-10-08 | Pentech Pharmaceuticals, Inc. | Transdermal administration of apomorphine |
FR2783246B1 (fr) * | 1998-09-11 | 2000-11-17 | Aventis Pharma Sa | Derives d'azetidine, leur preparation et les medicaments les contenant |
AU1732401A (en) * | 1999-12-10 | 2001-06-18 | Takeda Chemical Industries Ltd. | Medicinal compositions for oral use |
US6355631B1 (en) * | 2000-03-03 | 2002-03-12 | Aventis Pharma S.A. | Pharmaceutical compositions containing azetidine derivatives, novel azetidine derivatives and their preparation |
-
2001
- 2001-08-29 FR FR0111200A patent/FR2829028B1/fr not_active Expired - Fee Related
-
2002
- 2002-08-27 AR ARP020103211A patent/AR036302A1/es not_active Application Discontinuation
- 2002-08-28 DE DE60212148T patent/DE60212148T2/de not_active Expired - Lifetime
- 2002-08-28 ES ES02772514T patent/ES2263816T3/es not_active Expired - Lifetime
- 2002-08-28 PT PT02772514T patent/PT1423145E/pt unknown
- 2002-08-28 AU AU2002337277A patent/AU2002337277B2/en not_active Ceased
- 2002-08-28 AT AT02772514T patent/ATE328609T1/de not_active IP Right Cessation
- 2002-08-28 IL IL16055702A patent/IL160557A0/xx unknown
- 2002-08-28 CA CA002458348A patent/CA2458348A1/en not_active Abandoned
- 2002-08-28 JP JP2003524621A patent/JP2005505551A/ja not_active Ceased
- 2002-08-28 DK DK02772514T patent/DK1423145T3/da active
- 2002-08-28 EP EP06000097A patent/EP1649849A3/fr not_active Withdrawn
- 2002-08-28 WO PCT/FR2002/002946 patent/WO2003020314A1/fr active Application Filing
- 2002-08-28 MX MXPA04001645A patent/MXPA04001645A/es not_active Application Discontinuation
- 2002-08-28 EP EP02772514A patent/EP1423145B1/fr not_active Expired - Lifetime
-
2004
- 2004-02-25 US US10/786,810 patent/US7217705B2/en not_active Expired - Fee Related
-
2006
- 2006-08-31 CY CY20061101241T patent/CY1105341T1/el unknown
-
2007
- 2007-04-04 US US11/696,485 patent/US20070197654A1/en not_active Abandoned
-
2008
- 2008-08-07 IL IL193325A patent/IL193325A0/en unknown
- 2008-09-05 AU AU2008212039A patent/AU2008212039A1/en not_active Abandoned
-
2009
- 2009-12-09 JP JP2009279071A patent/JP2010053153A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
IL193325A0 (en) | 2009-02-11 |
FR2829028A1 (fr) | 2003-03-07 |
DE60212148T2 (de) | 2007-04-19 |
EP1423145A1 (fr) | 2004-06-02 |
JP2005505551A (ja) | 2005-02-24 |
PT1423145E (pt) | 2006-09-29 |
EP1649849A2 (fr) | 2006-04-26 |
EP1423145B1 (fr) | 2006-06-07 |
AR036302A1 (es) | 2004-08-25 |
FR2829028B1 (fr) | 2004-12-17 |
ATE328609T1 (de) | 2006-06-15 |
IL160557A0 (en) | 2004-07-25 |
US20070197654A1 (en) | 2007-08-23 |
US20040209861A1 (en) | 2004-10-21 |
JP2010053153A (ja) | 2010-03-11 |
CA2458348A1 (en) | 2003-03-13 |
DE60212148D1 (de) | 2006-07-20 |
EP1649849A3 (fr) | 2006-11-02 |
AU2002337277B2 (en) | 2008-06-05 |
AU2008212039A1 (en) | 2008-10-09 |
DK1423145T3 (da) | 2006-10-02 |
US7217705B2 (en) | 2007-05-15 |
WO2003020314A1 (fr) | 2003-03-13 |
CY1105341T1 (el) | 2010-03-03 |
ES2263816T3 (es) | 2006-12-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA04001645A (es) | Dispositivo de control de insectos que contiene coumaphos y diazinon para el tratamiento prolongado de animales. | |
AU2002337277A1 (en) | Compositions for the treatment of Parkinson's disease containing CB1 receptor antagonist and a product that activates dopaminergic neurotransmission in the brain | |
MXPA04001848A (es) | Asociacion de un antagonista del receptor cb1 y de un producto que activa la neurotransmision dopaminergica en el cerebro, las composiciones farmaceuticas que los contienen y su utilizacion para el tratamiento de la enfermedad de parkinson. | |
MX9801305A (es) | Composicion de disolucion rapida oral para agonistas de dopamina. | |
HUP0402026A3 (en) | 5,6-diaryl-pyrazine-2-amide derivatives as cb1 antagonists, process for their preparation and pharmaceutical compositions containing them | |
TW200505483A (en) | New medicament compositions based on anticholinergically-effective compounds and β-mimetics | |
GEP20063741B (en) | Nonaryl-Heterocyclic NMDA/NR2B Antagonists | |
MXPA05013711A (es) | Derivados 3-sustituidos de 5,6-diaril-pirazin-2-carboxi-amida y -2-sulfonamida, como moduladores de cb1. | |
MXPA05009103A (es) | Derivados de 2-oxo-1,3,5-perhidrotriazapina utiles en el tratamiento de trastornos hiper-proliferativos, por angiogenesis, e inflamatorios. | |
MY127980A (en) | A pyrrolidineacetamide derivative alone or in combination for treatment of cns disorders | |
HUP0400246A3 (en) | 1,2,4-trioxolane antimalarial pharmaceutical compositions and process for their preparation and use | |
MXPA04000886A (es) | Derivados de triazolil-imidazopiridina y triazolilpurinas empledos como ligandos del receptor de adenosina a2a y su uso como medicamentos. | |
NZ509762A (en) | 5-Azatricyclo[3.3.1.1<3,7>]decane derivatives, pharmaceuticals thereof, and their use as cholinergic receptor agonists and antagonists | |
MXPA04003298A (es) | Compuestos de piperidina como antagonistas muscarinicos. | |
HUP0301228A3 (en) | 3-azabicyclo(3.1.0)hexane derivatives having opioid receptor affinity, process for their preparation and pharmaceutical compositions containing them | |
HK1104280A1 (en) | Derivatives of 1-phenylalkanecarboxylic acids for the treatment of neurodegenerative diseases | |
HUP0401325A3 (en) | Isoxazolopyridinones useful in the treatment of parkinson's disease, process for their preparation and pharmaceutical compositions containing the compounds | |
BG104179A (en) | Phanquinon administration for the treatment of the alzheimer's disease | |
MXPA04005552A (es) | Analogos de vitamina d. | |
HK1060558A1 (en) | 2H-1-benzopyran derivatives, processes for their preparation and pharmaceutical compositions thereof. | |
WO2004046096A3 (en) | Novel ligands that are antagonists of raf receptors, process for preparing them and use thereof in human medicine and in cosmetics | |
RS60604A (en) | Carboxamidine derivatives and their use in the treatment of vascular diseases | |
ATE518842T1 (de) | Neue antagonistische derivate des vitronektinrezeptors, ihr herstellungsverfahren, ihre anwendung als arzneimittel und die pharmazeutischen zusammensetzungen, die sie enthalten | |
WO2002069944A3 (de) | Neue arzneimittelkompositionen auf der basis von anticholinergika und nk1-rezeptor-antagonisten | |
MXPA05007253A (es) | Sales novedosas de derivados anticonvulsivantes. |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FA | Abandonment or withdrawal |